RSV Vaccines: The Road to Licensure


Hana M. El Sahly, MD

BCM

19January2024


• I have no conflicts of interest to disclose

Viral Vaccines to Prevent Bacterial Drug Resistance?




Viral Vaccines to Prevent Bacterial Drug Resistance?


- In 2000: Ontario implemented universal flu vaccination
- Other provinces: targeted flu vaccination
- Outcome: effect of flu vaccination strategy on antibiotic prescriptions



Morbidity and Mortality of RSV in the US



Children younger than 5 years of age



medical encounters

Adults aged \geq 65 years

Thompson et al, JAMA 2003; Hansen et al JAMA Netw Open 2022; Hall et al, NEJM 2009; McLaughlin et al, J Infect Dis 2022.

Whole inactivated RSV vaccine The 1960s

- Population: infants 2-7m old
- Intervention 3 doses of RSV vaccine
- Control: parainfluenza virus vaccine
- Endpoint: immunogenicity and RSV infection

_		RSV vaccine Group (N=31)	PIV Vaccine Group (N=40)
/	4fold rise in Neut Ab	43%	Not Done
-	4fold rise in Comp Fix Ab	91%	15%
)	RSV infection	65%	53%
	Hospitalization (among RSV infected)	80%*	5%
		*7 dootbo	


*2 deaths

Road to RSV VACCINES WAS BLOCKED FOR DECADES



RSV vaccine development-Back to the Bench


- Majority of Neut Ab are targeted against preF
- The preF state can be locked via the introduction of specific mutations
- Vaccines based on preF antigen generated much higher levels of Neut Ab
- Implications for COVID-19 vaccines



Ph3 clinical trials-RSV clinical trials

- GSK: Prefusion-stabilized F protein adjuvanted with AS01_E, 120 mcg, RSV A: Elderly, and pregnancy study (aborted)
- Pfizer: Prefusion-stabilized F protein, bivalent 60mcg RSV A+60mcg RSV B. (Elderly, pregnant women)
- 3. Ad26-based product: development halted despite favorable VE data (?fallout from Covid-19 vaccine safety signal)
- 4. mRNA-1345: expresses Prefusion-stabilized F protein. Favorable VE data.

RSVpreF Ph3 Study Design



1. Efficacy endpoints:

Efficacy of the vaccine against RSV-related lower respiratory tract infection (LRTI) with 2 symptoms Efficacy against RSV-related LRTI with 3 symptoms


2. Tolerability and Safety Endpoints

RSVpreF Ph3 Study Population

Characteristic	RSVpreF N=16306 n (%)	Placebo N=16308 n (%)
Sex		
Male	8327 (51.1)	8225 (50.4)
Female	7979 (48.9)	8083 (49.6)
Age, years		
60-69 years	10176 (62.4)	10191 (62.5)
70-79 years	5207 (31.9)	5196 (31.9)
≥80 years	923 (5.7)	921 (5.6)
Male Female Age, years 60-69 years 70-79 years	8327 (51.1) 7979 (48.9) 10176 (62.4) 5207 (31.9)	8225 (50.4) 8083 (49.6) 10191 (62.5) 5196 (31.9)

With ≥1 prespecified significant condition: 51% (vaccine) vs 51.5% (placebo) Chronic obstructive pulmonary disease (COPD): 5.6% (vaccine) vs 6.1% (placebo) Congestive heart failure (CHF): 1.7% (vaccine) vs 1.8% (placebo)

RSVpreF Ph3 Efficacy against LRTI through mid-season 2



Walsh et al, NEJM 2023, 21jun2023ACIP meeting www.cdc.gov

RSVpreF Ph3 Safety and Tolerability

	RSVpreF N=3619-3621	Placebo N=3532-3539
Solicited Adverse Reaction	n (%)	n (%)
Local reaction ≥ Grade 1	441 (12.2)	235 (6.6)
Grade 3	8 (0.2)	2 (<0.1)

Solicited Adverse Reaction	RSVpreF N=3619-3621 n (%)	Placebo N=3532-3539 n (%)
Systemic reaction ≥ Grade 1	994 (27.5)	909 (25.7)
Grade 3	27 (0.7)	20 (0.6)

RSVpreF Safety and Tolerability (20,255 participants)


- Atrial fibrillation events in the vaccine (10) vs placebo (4) occurred between 18-30 days post injection
- Guillain-Barre Syndrome: 66 yoM, 7 days post-vaccination, hospitalized, resolving, 68 yo, 21 days post-vaccination
- Miller Fisher Syndrome: 66 yoF, 8 days post-vaccination; hospitalized, resolved by 3 month
- Motor-sensory axonal polyneuropathy: 68 yo, 21 days post-vaccination
- No cases in placebo
- Incidence of GBS in the general population: 1-3 per 100,000 (higher in older persons).

RSVpreF licensing status in the US

The RSVpreF vaccines was approved by the FDA on 31May2023 with a pharmacovigilance plan requirement to report on the following:

- 1. Full study data to FDA
- 2. Supraventricular arrhythmia events
- 3. Guillain Barré Syndrome and other demyelinating conditions

RSV PreF immunogenicity




• No data on repeated dosing for the RSV PreF vaccine

VRBPAC presentation 28Feb2023 at www.fda.gov

RSVpreF co-administration with seasonal flu vaccine


- · Placebo-controlled, double-blind study
- Assessing safety and immunogenicity (non-inferiority)
- Australia (31 sites)
- ~1,400 healthy participants ≥ 65 years of age
- Randomized 1:1
- SIIV: Fluad Quadrivalent
- Timeframe: April 13, 2022 October 12, 2022



RSVpreF co-administration with seasonal flu vaccine

Comparison, by SIIV/RSV Subg	roup	GMR (95% CI)
SIIV: HAI: H1N1 A/Victoria	⊢	0.86 (0.769, 0.963)
SIIV: HAI: H3N2 A/Darwin	⊢ I	0.77 (0.680, 0.866)
SIIV: HAI: B/Austria	بـــــ	0.90 (0.789, 1.019)
SIIV: HAI: B/Phuket	⊢ i	0.87 (0.779, 0.964)
RSVpreF: NT: RSV A	⊢ i	0.86 (0.785, 0.951)
RSVpreF: NT: RSV B	⊢ I	0.85 (0.766, 0.943)
	0.667 1.0 GMT Ratio	1.5

RSVpreF-AS01_E Ph3 Study Design



RSVpreF-AS01_E Ph3 Study-Study Population

	RSVpreF3-AS01 _E	Placebo
Characteristic	N=12467	N=12499
Sex, n (%)		
Male	5979 (48.0)	6072 (48.6)
Female	6488 (52.0)	6427 (51.4)
Age, years		
Mean age (SD)	69.0 (6.5)	69.6 (6.4)
Median age (min, max)	69.0 (59, 102)	69.0 (59 <i>,</i> 98)
60-69 YOA	6963 (55.9)	6980 (55.8)
70-79 YOA	4487 (36.0)	4491 (35.9)
≥80 YOA	1017 (8.2)	1028 (8.2)
At least 1 pre-existing Cardiorespiratory condition	2496 (20.0)	2422 (19.4)

RSVpreF-AS01_E Efficacy against RSV-LRTD

	Median	Vaccine	Placebo					
	Follow-Up (months)		Number of events					VE (95% CI)
Single Dose								W/o season as covariate#
Season 1* VE 1	6.7	7 / 12,466	40 / 12,494			-	•	82.6% (57.9, 94.1)
Mid Season 2 Post dose 1	14	15 / 12,469	85 / 12,498					80.9% [#] (66.7, 89.8)
Season 2 Only Post dose 2	6.4	20 / 4,991	91 / 10,031			•	-	56.1% (28.2, 74.4)
Season 1 + 2**	18	30 / 12,469	139 / 12,498	I	I	-		74.5% # (60.0, 84.5)
			C) 20	40	60	80	100

RSVpreF-AS01_E Efficacy against severe RSV-LRTD

	Median	Vaccine	Placebo						VE
	Follow-Up (months)	Number of events						(95% CI)	
Single Dose									W/o season as covariate [#]
Season 1* VE 1	6.7	1 / 12,466	17 / 12,494			-		•	94.1% (62.4, 99.9)
Mid Season 2 Post dose 1	14	4 / 12,469	33 / 12,498			H		I	86.8% # (63.0, 96.6)
Season 2 Only Post dose 2	6.4	5 / 4,991	28 / 10,031			•			64.2% (6.2, 89.2)
Season 1 + 2**	18	7 / 12,469	48 / 12,498			-		-	82.7% [#] (61.6, 93.4)
				0 20	40	60	80	10	0

RSV PreF3-Ad Tolerability Data

	RSV Vaccine N = 879	Placebo N = 878
Any solicited AE (within 4 days)	72%	28%
Administration site AEs	62%	10%
Systemic AEs	49%	23%
Grade 3 AEs	4%	0.9%
	Expose	ed Set
Within 30 days of vaccination	RSV Vaccine N = 12,467	Placebo N = 12,499
Any unsolicited AE*	33%	18%
Any medically attended AE	6%	6%

Adverse Events of concerns ~ 15000 participants

1. Numerical imbalance: atrial fibrillation within 30Days: Vaccine group=10 vs. placebo group=4.

2. Two cases of acute demyelinating encephalomyelitis (71 yo man/71yo woman), both occurred 22 days post vaccination, one fatal-Diagnosis ascertainment called into question.


3. One case of GBS: 78 yo woman, 9 days post vaccine. Required hosp for 6 months.

RSV PreF-AS01_E/Flu Vax High dose CoAdmin

			GMT Ratio (Control Over Co-Administration)	
Antibody	Co-Ad N	Control N	1 Month After Vaccination Per Protocol Set	GMT Ratio (95% CI)
Flu A/Darwin H3N2	458	441		0.98 (0.84, 1.14)
Flu A/Victoria H1N1	452	435		0.93 (0.80, 1.08)
Flu B/Austria/Victoria	458	441		0.95 (0.88, 1.03)
Flu B/Phuket/Yamagata	456	441		0.92 (0.84, 1.02)
RSV-A*	459	358		1.18 (1.04, 1.35)
RSV-B	459	357		1.02 (0.89, 1.16)
		0.5	5 1	1.5

- N=1008, 65 years of age or older, randomized 1:1 high-dose flu vaccine vs RSV PreF-Ad
- When standard dose influenza vaccine was the comparator in younger adults, responses to influenza and RSV antigens were diminished.

RSVpreF-AS01_E: immunogenicity of repeated dosing



A second dose of RSVPreF-AS01_E did not boost antibody responses to levels comparable to first dose response: an unusual finding for protein-based vaccines.

RSVpreF-AS01_E licensing status in the US

- RSVpreF-AS01_E was approved on 03May2023 with a pharmacovigilance plan requirement to report to the FDA back on the following:
- 1. ADEM
- 2. Guillain Barré Syndrome and other demyelinating conditions
- 3. Supraventricular arrhythmia events



QUESTIONS?

• hanae@bcm.edu